Should You Buy Cardiff Oncology Inc (CRDF) Stock Thursday Morning?

Cardiff Oncology Inc (CRDF) is higher by Thursday morning, with the stock gaining 1.69% in pre-market trading to 1.2. CRDF's short-term technical score of 62 indicates that the stock has traded more bullishly over the last month than 62% of stocks on the market. In the Biotechnology industry, which ranks 135 out of 146 industries, CRDF ranks higher than 78% of stocks. Cardiff Oncology Inc has fallen 36.22% over the past month, closing at $1.79 on September 7. During this period of time, the stock fell as low as $1.28 and as high as $2.02. CRDF has an average analyst recommendation of Strong Buy. The company has an average price target of $8.50.

CRDF has an Overall Score of 62. Find out what this means to you and get the rest of the rankings on CRDF!

See Full CRDF Report

Cardiff Oncology Inc has a Long-Term Technical rank of 52. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 48% of the market scoring higher. In the Biotechnology industry which is number 136 by this metric, CRDF ranks better than 136% of stocks.

Important Dates for Investors in CRDF:

-Cardiff Oncology Inc is set to release earnings on 2023-11-02. Over the last 12 months, the company has reported EPS of $-0.90. -We do not have a set dividend date for Cardiff Oncology Inc at this time. Click Here To Get The Full Report on Cardiff Oncology Inc (CRDF)